IFNB1 and central nervous system cancer: Recently, one study attempted to combine IFN-β treatment together with a novel, effective, cyclin-dependent kinase (CDK) inhibitor (TG02), which is used clinically to treat GBM (Le Rhun et al. 2019; Su et al. 2018; Wu et al. 2017), resulting in synergistic functions in human glioma models (Lohmann et al. 2020).